NCT06291376: An ongoing trial by Alexion Pharmaceuticals, Inc.
This trial is ongoing. It must report results 1 year, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06291376 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 29, 2024 |
| Completion date | Jan. 5, 2026 |
| Required reporting date | Jan. 5, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 1, 2025 |
| Days late | None |